Working through the start-up activities

 

“We are currently working through the start-up activities for the APeX-1 trial of BCX7353 for prevention of angioedema attacks in HAE patients and are targeting the end of the year to report results,” said Jon P. Stonehouse, President & CEO of BioCryst Pharmaceuticals, Inc. “In addition, we are conducting a Phase 1 clinical pharmacology study in healthy volunteers to determine if we are able to meaningfully increase exposure and get to a twice-daily oral dosage form of avoralstat. We expect to report results from this study this summer.”

(Source: BioCryst)

2016-05-06T01:54:37+00:00